AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02699125
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks
Trial: NCT02390960
Drug: Sildenafil Cream
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be instructed to apply pre-weighed SST-6006 to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
Trial: NCT00253929
Drug: intra-arterial infusion of sodium nitroprusside
RxNorm normalized name: methotrexate
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03551067
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine mixed with juice was given to the child orally preoperatively.
Trial: NCT01512108
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).
Trial: NCT03205176
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib, 300 mg, will be taken BID as oral capsules.
Trial: NCT01548066
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
Trial: NCT02327494
Drug: neuromuscular blockade
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: to determine the influence on oxygantion saturation parameters of the administration of neuromuscular blockade drug, rocuronio, to provide intense neuromuscular blockade during laparoscopic colorectal surgery
Trial: NCT00977587
Drug: Saccharomyces Cerevisiae CNCM I-3856
RxNorm normalized name: SACCHAROMYCES CEREVISIAE VAR. BOULARDII CNCM I-1079
DrugBank: Saccharomyces cerevisiae (DB10447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces cerevisiae CNCM I-3856, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).subjects will take 1 capsule twice a day
Trial: NCT02596828
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed
Trial: NCT02596828
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
Trial: NCT01290744
Drug: Clofazimine
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofazimine 100mg daily for 12 months after completion of MDT.
Trial: NCT02596828
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
Trial: NCT02596828
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
Trial: NCT04357483
Drug: flowable thrombin containing collagen hemostat matrix
RxNorm normalized name: collagen hemostat
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 5 ml flowable hemostat matrix (CollaStat®) was applied to the stump or anastomosis site after pancreatectomy.
Trial: NCT04357483
Drug: thrombin coated L-dopa contained collagen patch
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 5x2.5cm sized thrombin coated L-dopa contained collagen patch (CollaSeal®) was applied to the stump or anastomosis site after pancreatectomy.
Trial: NCT01819441
Drug: Azelnidipine
RxNorm normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8mg or 16mg
Trial: NCT01819441
Drug: Perindopril
RxNorm normalized name: Perindopril
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4mg or 8mg
Trial: NCT01819441
Drug: hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12.5mg or 25mg
Trial: NCT00946790
Drug: Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02979561
Drug: Dabigatran Etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients in this group continue to receive unfractionated heparin for 5-7 days, and then transferred to the drug Pradaxa dose of 150 mg 2 times a day. Pradaxa administration continued until the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
Trial: NCT02979561
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all patients continue to receive unfractionated heparin intravenously and at the same time (from the date of randomization) start warfarin, accompanied by regular measurement of the INR every day or every other day. As soon as INR reaches the range of 2.0 to 3.0, the administration of the unfractionated heparin should be discontinued. Further measurements of INR should be performed once a month during outpatient visits. The patient continues to receive warfarin under the control of the INR till the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
Trial: NCT01770145
Drug: APOKYN
RxNorm normalized name: Apokyn
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' best on UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes).
Trial: NCT03631199
Drug: canakinumab
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: canakinumab 200 mg subcutaneous (s.c.) injection every 3 weeks (squamous and non-squamous)
Trial: NCT03631199
Drug: canakinumab-matching placebo
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: canakinumab placebo every 3 weeks (squamous and non-squamous)
Trial: NCT00946790
Drug: Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03631199
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg every 3 weeks (squamous and non-squamous)
Trial: NCT03631199
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Area Under the Curve (AUC) 5 mg/mL\*min every 3 weeks (non-squamous) or AUC 6 mg/mL\*min (squamous)
Trial: NCT03631199
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m\^2 every 3 weeks (non-squamous)
Trial: NCT03631199
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg/m\^2 every 3 weeks (squamous)
Trial: NCT03631199
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg/m\^2 on Days 1, 8, and 15 of every cycle (squamous)
Trial: NCT03631199
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/m\^2 every 3 weeks (non-squamous)
Trial: NCT03614234
Drug: pegunigalsidase alfa
RxNorm normalized name: Pegunigalsidase alfa
DrugBank: Pegunigalsidase alfa (DB14992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human alpha galactosidase A
Trial: NCT03230565
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will be given a continuous infusion of local anesthetic.
Trial: NCT03230565
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will be given a scheduled intermittent bolus of local anesthetic.
Trial: NCT01019616
Drug: paclitaxel/anthracycline
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: standard chemotherapy regimen(containing paclitaxel or anthracycline) different from primary chemotherapy(containing anthracycline or paclitaxel)
Trial: NCT01770145
Drug: L-dopa
RxNorm normalized name: L-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.
Trial: NCT01770145
Drug: Trimethobenzamide
RxNorm normalized name: Trimethobenzamide
DrugBank: Trimethobenzamide (DB00662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duration of the APOKYN Initiation Period and APOKYN Treatment Period.
Trial: NCT00062205
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00005905
Drug: hu Leptin (A-100)
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00858676
Drug: acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg acarbose 3 times a day PO. duration: one year
Trial: NCT00307203
Drug: bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were randomly assigned to receive bupropion SR 150 mg or placebo, once daily for 7 days, then twice daily for 11 weeks.
Trial: NCT01740557
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00014170
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00307203
Drug: nicotine replacement therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.
Trial: NCT01429181
Drug: Non-racemic mixture of methadone HCl
RxNorm normalized name: brown mixture
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-racemic mixture of methadone HCl capsules, 5 mg
Trial: NCT01188304
Drug: aleglitazar
RxNorm normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: repeated daily doses
Trial: NCT01188304
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: repeated daily doses
Trial: NCT00461084
Drug: BIAXIN (CLARITHROMYCIN)
RxNorm normalized name: clarithromycin Oral Tablet [Biaxin]
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
Trial: NCT00461084
Drug: Biaxin (clarithromycin)
RxNorm normalized name: clarithromycin Oral Tablet [Biaxin]
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
Trial: NCT01463306
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin administered as either capsule or liquid oral formulations. Subjects \<4 years of age at Visit 1 will receive study medication 3 times daily (TID) in equally divided doses. Subjects who are ≥4 years of age at Visit 1 will receive study medication twice daily (BID) in equally divided doses. Children less than 17 years of age will receive from 2.5 mg/kg/day to 10.0 mg/kg/day (maximum 600 mg/day. Adults 17 and older will receive from 150 mg/day to 600 mg/day.
Trial: NCT02540876
Drug: Ilorasertib
RxNorm normalized name: Ilorasertib
DrugBank: Ilorasertib (DB11694)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00869570
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase II: 1 x 400 mg per day (during 5 weeks)
Trial: NCT03380026
Drug: Triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply up to three times daily on select lesions.
Trial: NCT01833572
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible participants will be given orally gefitinib 250mg daily before surgery for 42 days or until disease progression or unacceptable toxicity. Best supportive care is allowed in this period.
Trial: NCT03209466
Drug: Chlorhexidine gluconate at 0.125%
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
Trial: NCT03030950
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: to investigate the effect of dexmedetomidine on motor and sensory properties of adductor canal block
Trial: NCT00369746
Drug: citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets, 60 mg maximum, daily, 12 weeks
Trial: NCT00151541
Drug: Dapsone Topical Gel + adapalene gel 0.1%
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00151541
Drug: Dapsone Topical Gel + benzoyl peroxide gel 4%
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00151541
Drug: Dapsone Topical Gel + vehicle control
RxNorm normalized name: dapsone Topical Gel
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02071641
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01100359
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01166425
Drug: Lithium Carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID at visit 1 (total dose 900 mg). Participants weighing \< 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose. One mid-week dose increase will be scheduled in addition to the weekly increases at the scheduled in-clinic visits. On day 3 (+/- 2 days), a dose increase of 300 mg may occur based on the results of a telephone call placed by the study investigator to the participant's parent/guardian. During the telephone call, the prescribing clinician will assess medication adherence, adverse events, and overall improvement since baseline.
Trial: NCT02542813
Drug: IM oxytocin 10 IU
RxNorm normalized name: oxytocin 10 UNT/ML
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IM oxytocin 10 IU is a colourless and clear sterile solution in a 1 mL ampoule containing 10 IU of oxytocin, which is administered intramuscularly
Trial: NCT02542813
Drug: IH oxytocin 50 mcg
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IH oxytocin 50 mcg is a powder blend for inhalation in a hard capsule containing 50 mcg of oxytocin, which is administered by oral inhalation.
Trial: NCT03873324
Drug: CPL500036 compound
RxNorm normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).
Trial: NCT02542813
Drug: IH oxytocin 200 mcg
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IH oxytocin 200 mcg is a powder blend for inhalation in a hard capsule containing 200 mcg of oxytocin, which is administered by oral inhalation.
Trial: NCT00322699
Drug: Photofrin
RxNorm normalized name: Photofrin
DrugBank: Porfimer sodium (DB00707)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
Trial: NCT02542813
Drug: IH oxytocin 400 mcg
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IH oxytocin 400 mcg is a powder blend for inhalation in a hard capsule containing 400 mcg of oxytocin, which is administered by oral inhalation.
Trial: NCT02542813
Drug: IH oxytocin 600 mcg
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IH oxytocin 600 mcg is a powder blend for inhalation in a hard capsule containing 600 mcg of oxytocin, which is administered by oral inhalation.
Trial: NCT01966653
Drug: nitrofurantoin
RxNorm normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nitrofurantoin 100 mg po tid for 5 days
Trial: NCT03141632
Drug: Dulaglutide
RxNorm normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Evaluation visit with assessment of fluid intake
Trial: NCT01966653
Drug: fosfomycin
RxNorm normalized name: FOSFOMYCIN
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fosfomycin 3g po single dose
Trial: NCT04083651
Drug: Methylnaltrexone bromide
RxNorm normalized name: Methylnaltrexone Bromide
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
Trial: NCT03586544
Drug: Albuterol Sulfate
RxNorm normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will inhale 2 puffs of albuterol (90mcg per actuation). After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
Trial: NCT02787967
Drug: free comb. beclomethasone DPI and formoterol DPI
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
Trial: NCT00281918
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous repeating dose